EVT:NYE-Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest (USD)

ETF | Drug Manufacturers - Specialty & Generic | New York Stock Exchange

Last Closing

USD 24.61

Change

+0.19 (+0.78)%

Market Cap

USD 1.46B

Volume

0.12M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

The Funds investment objective is to provide a high level of after-tax total return consisting primarily of tax-advantaged dividend income and capital appreciation. Under normal market conditions, the Fund will invest at least 80% of its total assets in dividend-paying common and preferred stocks. The Fund may invest in common and preferred stocks of both domestic and foreign issuers. The Fund may invest up to 30% of its total assets in securities rated below investment grade.

Inception Date: 30/09/2003

Primary Benchmark: Russell 1000 Value TR USD

Primary Index: Morningstar Mod Tgt Risk TR USD

Gross Expense Ratio: 1.47%

Management Expense Ratio:

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-21 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Mer Price(Change) Market Cap
ZTS Zoetis Inc 0.00 %

-0.90 (-0.54%)

USD 76.41B
HLN Haleon plc 0.00 %

-0.02 (-0.22%)

USD 42.79B
TAK Takeda Pharmaceutical Co Ltd A.. 0.00 %

-0.21 (-1.60%)

USD 41.33B
RDY Dr. Reddy’s Laboratories Ltd.. 0.00 %

+0.29 (+1.96%)

USD 12.60B
ELAN Elanco Animal Health 0.00 %

+0.06 (+0.50%)

USD 5.65B
AMRX Amneal Pharmaceuticals, Inc. C.. 0.00 %

-0.04 (-0.47%)

USD 3.68B
BHC Bausch Health Companies Inc 0.00 %

+0.25 (+3.35%)

USD 2.91B
CPHI China Pharma Holdings Inc 0.00 %

-0.01 (-2.82%)

USD 3.69M
YCBD cbdMD Inc 0.00 %

-0.02 (-4.26%)

USD 1.96M
EBS Emergent Biosolutions Inc 0.00 %

+0.65 (+6.36%)

N/A

ETFs Containing EVT

FCEF First Trust Income Opport.. 0.00 % 0.85 %

-0.01 (0.00%)

USD 0.04B
E908:F Lyxor 1 - TecDAX UCITS ET.. 0.00 % 0.00 %

N/A

N/A
EXS2:F iShares TecDAX UCITS ETF .. 0.00 % 0.00 %

+0.06 (+0.00%)

N/A
E908:XETRA Lyxor 1 TecDAX (DR) UCITS.. 0.00 % 0.00 %

+0.22 (+0.00%)

USD 0.09B
EXS2:XETRA iShares TecDAX® UCITS ET.. 0.00 % 0.00 %

+0.17 (+0.00%)

USD 0.77B
EXIB:XETRA iShares TecDAX® UCITS ET.. 0.00 % 0.00 %

+0.03 (+0.00%)

USD 0.77B
CB1TX:SW Lyxor 1 TecDAX (DR) UCITS.. 0.00 % 0.00 %

+0.17 (+0.00%)

N/A
TDXPEX:SW iShares TecDAX® UCITS ET.. 0.00 % 0.00 %

N/A

USD 5,933.97B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.33% 71% C- 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.33% 71% C- 49% F
Trailing 12 Months  
Capital Gain 11.36% 64% D 59% D-
Dividend Return 8.06% 100% F 87% B+
Total Return 19.42% 71% C- 68% D+
Trailing 5 Years  
Capital Gain -5.35% 62% D 43% F
Dividend Return 34.34% 100% F 87% B+
Total Return 28.99% 69% C- 54% F
Average Annual (5 Year Horizon)  
Capital Gain 5.76% 43% F 53% F
Dividend Return 12.36% 71% C- 65% D
Total Return 6.60% 100% F 90% A-
Risk Return Profile  
Volatility (Standard Deviation) 25.52% 57% F 43% F
Risk Adjusted Return 48.44% 86% B+ 62% D
Market Capitalization 1.46B N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike